Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

GLYC


Fundamental

Company: Crescent Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -21.97
Insider Own: 19.80%
Shs Outstand: 27.56M
Perf Week: -5.99%
Market Cap: 246.39M
Forward P/E: -
EPS next Y: -5.34
Insider Trans: 33.20%
Shs Float: 22.10M
Perf Month: -29.22%
Enterprise Value: 118.87M
PEG: -
EPS next Q: -2.47
Inst Own: 41.80%
Short Float: 5.04%
Perf Quarter: -31.49%
Income: -55.96M
P/S: -
EPS this Y: 82.61%
Inst Trans: 10.54%
Short Ratio: 6.24
Perf Half Y: -35.82%
Sales: 0.00M
P/B: 1.10
EPS next Y Percentage: 47.93%
ROA: -72.70%
Short Interest: 1.11M
Perf YTD: -24.62%
Book/sh: 8.11
P/C: 1.85
EPS next 5Y: 58.90%
ROE: -87.43%
52W High: 37.00 -75.84%
Perf Year: -68.50%
Cash/sh: 4.84
P/FCF: -
EPS past 3/5Y: 21.89% 15.18%
ROIC: -47.44%
52W Low: 8.72 2.52%
Perf 3Y: -97.63%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 6.82%
Volatility M: 9.05%
Perf 5Y: -97.78%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 64.36%
Oper. Margin: -
ATR (14): 0.85
Perf 10Y: -97.71%
Dividend Ex-Date: -
Quick Ratio: 6.63
Sales Y/Y TTM: -100.00%
Profit Margin: -
RSI (14): 29.53
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 6.63
EPS Q/Q: 90.23%
SMA20: -17.08%
Beta: 1.35
Target Price: 30.14
Payout: -
Debt/Eq: 0.01
Sales Q/Q: -
SMA50: -23.82%
Rel Volume: 1.39
Prev Close: 9.23
Employees: 26
LT Debt/Eq: 0.01
Earnings: Nov 06 BMO
SMA200: -37.77%
Avg Volume: 178.33K
Price: 8.94
IPO: Jan 10, 2014
Option/Short: No / Yes
EPS/Sales Surpr.: 35.17% -
Trades:
Volume: 247,195
Change: -3.14%

Technical:


Latest News:

Glycobiology/Glycomics Market 2024 Growth Parameters – Thermo Fisher Scientific, Agilent ... somewhat bullish
TMO A EW WAT BRKR SIAL 7986JP PROZ DHR 7701JP

Summary: A new research report titled Global Glycobiology/Glycomics Market provides an in-depth analysis of a global market summarizing key uses, growth analysis, industry trends, and forecasts to 2032. The report offers a detailed picture of the current industrial situation incorporating authentic and anticipated market estimates in terms of value and volume. The report also includes a full analysis of raw material sourcing, significant suppliers, raw material price patterns, and an examination of the industrial chain.

Full article
2024-09-19T05:48:31Z
Capital One Financial Comments on GlycoMimetics, Inc.'s Q1 2024 Earnings (NASDAQ:GLYC) somewhat bearish
GLYC

Summary: Capital One Financial issued Q1 2024 EPS estimates for GlycoMimetics with a 'Equal Weight' rating. The consensus estimate for GlycoMimetics' full-year earnings is ($0.54) per share. Several brokerages commented on GLYC, with StockNews.com downgrading it and HC Wainwright maintaining a 'neutral' rating.

Full article
2024-05-09T10:51:04Z
Dow Launches Bio-Circular and Circular Propylene Glycol Solutions in North America somewhat bullish
DOW

Summary: Dow (NYSE: DOW) launches two new sustainable varieties of propylene glycol solutions in North America, featuring bio-circular and circular feedstocks, aiming to offer high-performance products with sustainability benefits.

Full article
2024-05-07T17:18:24Z